Last week, at a meeting of the American Society of Clinical Oncology, ASCO President George Sledge painted a hopeful, but also challenging, picture about new genomic technologies for fighting cancer. These technologies can unravel the genetic mechanisms driving the disease and point the way to new strategies to overcome cancer-drug resistance.
Sledge’s enthusiasm was balanced by realism: Revolutionary progress against cancer will depend not so much on the technology we use, as on our ability to rethink old paradigms for drug development and Food and Drug Administration drug approval.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.